ECSP10010188A - Productos quimioterapéuticos cristalinos derivados de indazol - Google Patents

Productos quimioterapéuticos cristalinos derivados de indazol

Info

Publication number
ECSP10010188A
ECSP10010188A EC2010010188A ECSP10010188A ECSP10010188A EC SP10010188 A ECSP10010188 A EC SP10010188A EC 2010010188 A EC2010010188 A EC 2010010188A EC SP10010188 A ECSP10010188 A EC SP10010188A EC SP10010188 A ECSP10010188 A EC SP10010188A
Authority
EC
Ecuador
Prior art keywords
indazol
therapeutic products
chemical therapeutic
crystal chemical
crystal
Prior art date
Application number
EC2010010188A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Michael J Rozema
Shailendra V Bordawekar
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010188(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP10010188A publication Critical patent/ECSP10010188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea hidrato, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento de pacientes que padecen una enfermedad para usarla.
EC2010010188A 2007-10-19 2010-05-18 Productos quimioterapéuticos cristalinos derivados de indazol ECSP10010188A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98123607P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010188A true ECSP10010188A (es) 2010-06-29

Family

ID=40090209

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010188A ECSP10010188A (es) 2007-10-19 2010-05-18 Productos quimioterapéuticos cristalinos derivados de indazol

Country Status (24)

Country Link
US (2) US7947843B2 (es)
EP (1) EP2195298B1 (es)
JP (1) JP5517940B2 (es)
KR (1) KR20100085116A (es)
CN (1) CN101827822B (es)
AR (1) AR068917A1 (es)
AU (1) AU2008312529A1 (es)
BR (1) BRPI0818065A8 (es)
CA (1) CA2699352C (es)
CL (1) CL2008003090A1 (es)
CO (1) CO6280481A2 (es)
CR (1) CR11388A (es)
DO (1) DOP2010000115A (es)
EC (1) ECSP10010188A (es)
ES (1) ES2460951T3 (es)
MX (1) MX2010004286A (es)
PA (1) PA8800201A1 (es)
PE (1) PE20091385A1 (es)
RU (1) RU2010119928A (es)
SG (1) SG185327A1 (es)
TW (1) TW200934485A (es)
UA (1) UA99746C2 (es)
UY (1) UY31407A1 (es)
WO (1) WO2009052226A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CN101346128B (zh) 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
BRPI0818065A8 (pt) 2016-03-08
SG185327A1 (en) 2012-11-29
CN101827822B (zh) 2013-06-19
MX2010004286A (es) 2010-04-30
JP2011500705A (ja) 2011-01-06
BRPI0818065A2 (pt) 2015-03-31
WO2009052226A1 (en) 2009-04-23
KR20100085116A (ko) 2010-07-28
UA99746C2 (ru) 2012-09-25
PA8800201A1 (es) 2009-05-15
AR068917A1 (es) 2009-12-16
US7947843B2 (en) 2011-05-24
US8486988B2 (en) 2013-07-16
DOP2010000115A (es) 2010-10-15
CR11388A (es) 2010-10-05
RU2010119928A (ru) 2011-11-27
CO6280481A2 (es) 2011-05-20
CN101827822A (zh) 2010-09-08
EP2195298B1 (en) 2014-02-19
US20110196010A1 (en) 2011-08-11
US20090118344A1 (en) 2009-05-07
JP5517940B2 (ja) 2014-06-11
CL2008003090A1 (es) 2009-11-27
ES2460951T3 (es) 2014-05-16
UY31407A1 (es) 2009-05-29
EP2195298A1 (en) 2010-06-16
CA2699352C (en) 2016-06-21
AU2008312529A1 (en) 2009-04-23
TW200934485A (en) 2009-08-16
PE20091385A1 (es) 2009-11-12
CA2699352A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
ECSP10010188A (es) Productos quimioterapéuticos cristalinos derivados de indazol
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
BRPI0415643A (pt) uso de ifenprodil no tratamento de dor
TN2011000037A1 (en) Treatment of pulmonary arterial hypertension